# Milrinone

Drug · id `cardio:milrinone` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Milrinone lactate

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Acute care and long-term living  

## In plain language

Milrinone is a medicine given into a vein. A US label for milrinone lactate injection lists it for short-term treatment of patients with acute decompensated heart failure. The label describes it as a positive inotrope, a medicine that strengthens the heartbeat, and a vasodilator, which widens blood vessels. The label says patients receiving it "should be observed closely with appropriate electrocardiographic equipment" and that treatment for "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours."

## Technical summary

RxNorm ingredient 52769; UNII 9K8XR81MO8 is the UNII of the salt, milrinone lactate, that the label gives, so it is a broad match; MeSH descriptor D020105 (Milrinone). US drug-label class: Phosphodiesterase 3 Inhibitor (established pharmacologic class, RxClass). The MeSH scope note says it inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. The label read is the Hikma Pharmaceuticals USA label for milrinone lactate (vial and premixed dextrose forms), application ANDA077966, effective 2025-05-08 in openFDA; openFDA lists many other milrinone labels, which were not read. This page records the label indication and the class only: no trial result and no dose is given. The parent class page (inotropes and vasopressors) is not written yet, so the page has no parent link.

## Claims, with the population each applies to

## Context: Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure

Recipient: Recipient not specified; Population: Patients with acute decompensated heart failure, as the indications section describes them; the sentence does not name an age group.; Care setting: Intravenous medicine used with close observation and electrocardiographic equipment, as the indications section describes; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the indication sentence; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of milrinone lactate injection (Hikma Pharmaceuticals, abbreviated application ANDA077966; version dated 8 May 2025 in openFDA) lists the medicine for short-term intravenous treatment of patients with acute decompensated heart failure. The same section says that patients receiving milrinone "should be observed closely with appropriate electrocardiographic equipment" and that the facility for immediate treatment of "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours." The label describes the medicine as a positive inotrope and vasodilator with little chronotropic activity.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with acute decompensated heart failure, as the indications section describes them; the sentence does not name an age group.; Care setting: Intravenous medicine used with close observation and electrocardiographic equipment, as the indications section describes; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the indication sentence; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses, interactions and adverse reactions were not recorded. The label covers both the vial and the premixed dextrose product. openFDA says its data are unvalidated and not to be relied on for decisions about medical care. openFDA lists many other milrinone labels from other makers, which were not read.
- Last checked: 2026-11-08
- Sources:
  1. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  2. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  3. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].openfda.brand\_name\[0\]. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  4. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 1. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  5. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 2. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  6. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 3. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  7. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 5. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.
  8. Supports: openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966) (Label, edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88f78780-399f-4780-be19-205739db1682>
     Locator: results\[0\].clinical\_pharmacology\[0\], 1. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: 852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d.
     How it applies: Quoted at this locator.

## Connected pages

- The US label lists short-term intravenous treatment of acute decompensated heart failure: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-milrinone-label-indications` and its context]
- Filed under this front: Medicines (`cardio:front-medicines`)
- The US label calls milrinone a positive inotrope and vasodilator: Inotropes and vasopressors (`cardio:inotropes-and-vasopressors`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 2 registry products
- 2 registry trials

## Provenance

Content hash: 88d6d1b68f556082ab245dfcc223ff5470d15f20218759cf42343f51c7078763
Last substantive edit: 2026-11-08
Evidence last checked: 2026-11-08
